Tremella

Tremella (Tremella fuciformis Berk.): A Comprehensive Reference

1. Identity, Taxonomy, and Natural Source

Tremella fuciformis is an edible and medicinal fungus possessing notable medicinal properties and bioactivities in its fruiting bodies. It belongs to the order Tremellales and the family Tremellaceae, exhibiting numerous clusters of flat, flaky, or wavy leaflets. According to the NCBI Taxonomy Browser, its full classification situates it within the kingdom Fungi, phylum Basidiomycota, class Tremellomycetes, order Tremellales, and family Tremellaceae, with Taxonomy ID 64657.

The genus Tremella was one of the original genera created by Linnaeus in his Species Plantarum of 1753; the name comes from the Latin tremere, meaning "to tremble." Linnaeus originally placed Tremella in the algae, grouping within it a variety of gelatinous growths, including seaweeds, cyanobacteria, and myxomycetes as well as fungi. The species T. fuciformis was formally described by the British mycologist M.J. Berkeley in 1856, published in Hooker's Journal of Botany and Kew Garden Miscellany; its recognized synonyms include Nakaiomyces nipponicus Kobayasi, Tremella fuciformis f. corniculata Kobayasi, and Tremella nipponica (Kobayasi) Wojewoda.

The fruit bodies are gelatinous, watery white, up to 7 centimetres across (larger in cultivated specimens), and composed of thin but erect, seaweed-like, branching fronds, often crisped at the edges. It is a species of fungus producing white, frond-like, gelatinous basidiocarps (fruiting bodies), widespread especially in the tropics, where it can be found on the dead branches of broadleaf trees.

White jelly mushroom, Tremella fuciformis, is a popular edible mushroom with interesting medicinal properties, including immunostimulating and antidiabetic effects. The formation of T. fuciformis basidiomes is highly dependent on the presence of a specific host fungus, both in nature and for industrial production. It is a parasitic yeast that grows as a slimy, mucus-like film until it encounters its preferred hosts, various species of Annulohypoxylon (or possibly Hypoxylon) fungi.

1.1 Common Names

According to Paul Stamets, common names for T. fuciformis include: white jelly mushroom, yin er, white jelly fungus, white jelly leaf ("shirokikurage"), silver ear mushroom, snow mushroom, and chrysanthemum mushroom. Its names in other languages include "Silberohr" (German), "Hongo temblón de nieve" (Spanish), "Dрожалка фукусовидная" (Russian), and "シロキクラゲ" (Japanese). In China, it is known specifically as "silver fungus" or "white fungus."

1.2 Cultivation and Production

Tremella fuciformis has been cultivated in China since at least the nineteenth century. Initially, suitable wooden poles were prepared and treated in various ways in the aspiration that they would be colonized by the fungus. This haphazard method was improved when poles were inoculated with spores or mycelium. Modern production only began, however, with the realization that both the Tremella and its host species needed to be inoculated into the substrate to ensure success. Cultivation is now very widespread on synthetic soil inoculated with a mixed culture that also includes the ascomycete Hypoxylon archeri; the growth medium is typically made from sawdust of plants (78%), rice bran (20%), and CaCO₃ (2%) for a pH of 5.8 to 6.2, with the addition of egg powder (2–3% dry weight).

1.3 Common Supplement Forms

Tremella mushrooms grow in tropical climates on damp, dead or dying hardwood of broadleaf trees and are found in fresh, dried, and canned form, used to add texture to a wide variety of culinary applications. In supplement and pharmaceutical contexts, it is available as dried whole fruiting body, hot-water extracts, standardized polysaccharide extracts, enteric-coated capsules, and, increasingly, as a cosmetic ingredient. A standardized pharmaceutical form — "Tremella Polysaccharide Enteric-coated Capsules" — was approved by the Chinese Food and Drug Administration (SFDA) in 2002 for treating cancer patients with leukopenia induced by chemotherapy and radiotherapy.

2. Traditional and Historical Use

Tremella fuciformis was first mentioned in the Shennong Bencao Jing (Shennong's Classic of Materia Medica; approximately 200–300 AD). For thousands of years, T. fuciformis has been regarded as a precious traditional medicine for nourishing the stomach and lungs and improving weakness.

In Traditional Chinese Medicine, the fungus — known as "yin er" (silver ear) — has been documented since the Tang Dynasty (618–907 AD), where it was valued for its nourishing properties and incorporated into tonics for vitality and longevity. This early recognition is further elaborated in Li Shizhen's seminal Compendium of Materia Medica (Bencao Gangmu, 1596), which praises T. fuciformis for benefiting the lungs, stomach, and spleen while promoting fluid production and countering dryness.

In ancient times, like many of the other revered medicinal mushrooms such as Reishi and Cordyceps sinensis, Tremella was reserved for royalty, members of the ruling family, or rich people who could afford this highly valued superfood.

In the framework of Traditional Chinese Medicine (TCM), the Tremella mushroom (known as bai mu er, or "white wood ear") is considered an energetically sweet, bland, and neutral herb — meaning it neither warms nor cools the body. It is gently tonifying, considered suitable for young and old, all body constitutions, and for regular consumption, making it a popular kitchen medicinal. According to TCM principles, Tremella is considered a Yin tonic, helping to promote hydration and balance in the body. It is often used to support the health of the lungs, stomach, and skin; Tremella is believed to have cooling properties making it useful for soothing dry coughs, clearing heat, and alleviating dryness-related conditions such as constipation.

In traditional Chinese medicine, Tremella is used for hemorrhoids and all types of bleeding; in Europe it has been used for abscesses, abdominal pain, heart problems, and immune system deficiency. It is especially called upon during convalescence from chronic illness, where it features in comforting, restorative soups.

2.1 Traditional Preparations

In TCM, Tremella is traditionally taken by soaking around 3–4 grams for between 1–2 hours. It is then cooked down into a paste in an earthenware pot and eaten with sugar or mixed into a recipe. It is also common to take Tremella in its powdered form mixed in with food such as in smoothies or broths.

3. Key Constituents and Active Compounds

Tremella fuciformis contains a variety of bioactive ingredients, including fatty acids, proteins, enzymes, polysaccharides, phenols, flavonoids, dietary fibers, and trace elements. The chemical composition contains carbohydrates (70–80%, w/w), proteins (8–10%, w/w), fibers (2–3%, w/w), and trace amounts of lipids.

3.1 Tremella fuciformis Polysaccharides (TFPS/TFP)

T. fuciformis polysaccharide (TFPS) has been identified as a major bioactive component. Different experimental conditions can obtain different TFPS fractions, which makes TFPS a mixture of polysaccharides with molecular weight ranging from 5.82 × 10⁵ Da to 3.74 × 10⁶ Da. The monosaccharides detected in TFPS include mannose, xylose, fucose, glucuronic acid, glucose, and galactose.

One characterized TFPS chemical structure consists of a linear (1→3)-linked α-D-mannose backbone with highly branched β-D-xylose, α-D-fucose, and β-D-glucuronic acid as the side chains. TFPS has been identified as a major bioactive component in T. fuciformis, widely present in the fruiting body, spores, mycelia, and fermentation liquor.

One well-characterized bioactive polysaccharide, designated TFP-F1, has a high molecular weight of 1.87 × 10³ kDa. Its monosaccharide composition includes fucose, xylose, mannose, and glucuronic acid in a ratio of 0.9:1.0:3.2:1.2. Using IR, NMR, and GC-MS spectroscopic data, the structure was elucidated as a repeating sequence with partial acetylation of C6-OH in mannoses. The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.

3.2 Hyaluronic Acid and Related Polysaccharides

The polysaccharides of T. fuciformis have a structure made up of a straight chain of (1→3) α-D-mannan and side chains of glucuronic acid, xylose, and fucose; research has investigated whether non-animal hyaluronic acid extracted from T. fuciformis can maintain the chemical and physical characteristics of hyaluronic acid that ensure its biological functionality. Chemical characterization revealed that the most abundant polysaccharide in one characterized extract was hyaluronic acid, accounting for approximately 87.76%, with a molecular weight above 2,000 kDa. ATR/FTIR, NMR spectroscopy, and MALDI-TOF analysis confirmed that Tremella fuciformis extract can be a source of non-animal hyaluronic acid.

3.3 Phenolic Compounds and Flavonoids

Methanol extract subfractions of T. fuciformis have been assessed for antioxidant properties; among the subfractions tested, the chloroform subfraction exhibited the strongest antioxidant activity, with the highest total phenolic content (66.31 μg CAE/mg extract) and flavonoid content (5.12 μg QE/mg extract). This subfraction also demonstrated anti-inflammatory activity through inhibition of nitric oxide production and inducible nitric oxide synthase expression in RAW 264.7 cells.

3.4 Other Constituents

Tremella is rich in polysaccharides, triterpenoids, protein, dietary fiber, vitamins, and chitin. The mushroom, in addition to containing vitamins and minerals, is rich in copper due to its ability to accumulate copper from the growth substrate. The content of nutrients on a dry basis includes 4.6% protein, 0.2% fat, 1.4% fiber, and 0.4% ash.

4. Mechanisms of Action

4.1 Immunomodulation

TFPS plays a vital role in enhancing immune activities through the activation of macrophages, T lymphocytes, and B lymphocytes, and through the regulation of nonspecific immunity, humoral immunity, and cellular immunity. At a concentration of 1 μg/mL, the characterized polysaccharide TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).

In lipopolysaccharide-stimulated macrophage models, LPS induced inflammation, reactive oxygen species (ROS) production, and promoted the secretion of cytokines such as TNF-α and IL-6; it also enhanced the nuclear translocation of NFκB. However, pretreatment with TFPS profoundly inhibited the activation of Akt, p38MAPK, and NFκB and attenuated the expression of MCP-1 in macrophages.

4.2 Antioxidant Mechanisms

Tremella fuciformis is naturally rich in polysaccharides, which may contribute to anti-aging and antioxidant effects due to their ability to prevent cellular damage caused by free radicals. Oxidative stress, denoting the overproduction of reactive oxygen species within the body and resulting in the disturbance of redox equilibrium, incites cellular and tissue damage and increases many health risks including inflammatory responses, diminished immune function, and accelerated aging. Research has elucidated the connection between TFPS and the NRF2/HO-1 signaling pathway as part of its antioxidant mechanism at the molecular level.

4.3 Antitumor Mechanisms

One studied mechanism by which TFP exerts antitumor activity involves disruption of lipid metabolism: TFP induced expression of glucose transporter type 4 and CD36, resulting in an increase in lipid uptake, which suppressed downstream pathways and disrupted cell volume homeostasis, activated innate immune response, and thereby inhibited melanoma development and progression. These data revealed a novel molecular mechanism involved in the antitumor effect of TFP via lipid metabolism.

4.4 Neuroprotective Mechanisms

The neurotrophic effects of the hot water extract of T. fuciformis were evaluated by monitoring its potency to induce neurite outgrowth in PC12h cells; the hot water extract promoted neurite outgrowth in these cells, superior to other natural substances previously reported. When cells were treated with the hot water extract prior to β-amyloid peptide treatment, toxicity was significantly diminished (p<0.01).

In studies of purified polysaccharide fractions (TL04), treatment improved cell viability and suppressed reactive oxygen species accumulation, lactate dehydrogenase release and caspase-3 activity, and ameliorated mitochondrial abnormalities caused by glutamate. TL04 pretreatment enhanced the level of Bcl-2 and suppressed Bax expression and cytochrome c release; exposure to glutamate strongly increased the activity of caspase-8, caspase-9, and caspase-3, which were significantly reversed by TL04 pretreatment.

4.5 Anti-Inflammatory Mechanisms

In an animal model of colitis, high-dose Tremella polysaccharides (HTPs) could prevent the colon from shortening, reduce activity of colonic myeloperoxidase and serum diamine oxidase, decrease the concentration of D-lactate, and alleviate colonic tissue damage. HTPs treatment stimulated Foxp3⁺ T cells and promoted the production of anti-inflammatory cytokines, whereas it reduced the production of pro-inflammatory cytokines.

5. Scientific Evidence by Area of Use

5.1 Cognitive Function and Neuroprotection

Human/Clinical Evidence: In a published randomized controlled trial (RCT), individuals in the Tremella fuciformis (TF) group showed greater improvements in the total scores on the subjective memory complaint questionnaire compared with those in the placebo group. There were also significantly greater improvements in short-term memory and executive functions in the TF group relative to the placebo group. Exploratory analysis demonstrated that there were significant group-by-visit interactions on the left precuneus, right supramarginal gyrus, right middle frontal gyrus, and right postcentral gyrus at corrected P < .05. The overall frequency of adverse events did not differ among high-dose TF (40.4%), low-dose TF (35.1%), and placebo groups (41.4%). The findings suggest that TF could be safely administered to relieve subjective memory complaints and enhance cognition in individuals with subjective cognitive impairment (SCI).

The investigators noted that, to the best of their knowledge, there are no reports of major health risks associated with Tremella. They concluded that 1,200 milligrams per day of TF administration would be a safe and easily accessible intervention for individuals with SCI. In this study, no dose-dependent response was found; although executive performance was significantly improved only in the high-dose TF group, the dose group-by-time interaction effect was not significant.

Preclinical Evidence: Cell study results suggest that T. fuciformis might potentially be used as a precautionary agent in neurodegenerative disease such as Alzheimer's disease. In rat models, Tremella fuciformis has been shown to enhance the neurite outgrowth of PC12 cells and restore trimethyltin-induced impairment of memory via activation of CREB transcription and cholinergic systems.

Evidence Strength: There is one published RCT, supplemented by several preclinical (cell and animal) studies. The clinical evidence is preliminary and limited in scale; independent replication in larger, well-designed trials is required before firm conclusions can be drawn.

5.2 Blood Glucose Regulation (Antidiabetic Effects)

Human/Clinical Evidence: A double-blind RCT aimed to investigate the effects of a once-daily beverage containing Tremella fuciformis (snow mushroom) on anthropometric measurements, metabolic biomarkers, and insulin sensitivity in overweight/obese subjects with prediabetes, with 56 participants randomly assigned to receive either a Tremella fuciformis beverage or placebo daily for 12 weeks. After 12 weeks, participants in the intervention group exhibited significant improvements in glycated hemoglobin A1c (HbA1C; 6.03 ± 0.26% at baseline vs. 5.96 ± 0.25% at 12 weeks, p = 0.047, Cohen's d = 0.39) and waist circumference (95.2 ± 12.51 cm at baseline vs. 93.46 ± 11.48 cm at 12 weeks, p = 0.022, Cohen's d = 0.45). There were no adverse events reported. This exploratory study demonstrated that Tremella fuciformis beverage consumption may improve HbA1C and waist circumference in overweight/obese prediabetic individuals; further research, including larger-scale RCTs and mechanistic studies, is needed to confirm these findings.

Preclinical Evidence: Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of Tremella fuciformis have been demonstrated in ob/ob mice.

Evidence Strength: Preliminary. One small exploratory RCT in prediabetic individuals shows promising signals; however, the trial is limited by its small size and exploratory design. The finding requires confirmation in larger, adequately powered trials.

5.3 Immunomodulation and Support of Cancer Patients

Human/Clinical Evidence: In 2002, after approval by the Chinese Food and Drug Administration (CFDA), "Tremella Fuciformis polysaccharide enteric capsules" derived from TFPs were introduced to alleviate leukopenia symptoms in cancer patients undergoing chemotherapy and radiotherapy. Additionally, these capsules are widely used as adjuvant therapies for chronic persistent hepatitis, chronic active hepatitis, mycoplasma pneumonia, and subjective cognitive disorders, and other conditions.

A systematic review of 113 independent studies involving biochemical, pharmacological, and clinical studies of TFPS during the past 46 years (1972–2018), based on PubMed, CNKI, and Wanfang database searches, was conducted. TFPS shows efficacy for all types of human diseases in the reported clinical studies. Most clinical studies are related to the treatment of patients with leukopenia induced by chemotherapy, radiotherapy, and other causes.

Preclinical Evidence: Hot water extracts of T. fuciformis significantly augmented inducible nitric oxide synthase (iNOS), interleukin-6, and tumor necrosis factor mRNA expression in cell studies.

Evidence Strength: Moderate, within the Chinese clinical literature. The regulatory approval of an enteric-coated polysaccharide capsule by the Chinese SFDA for leukopenia management represents an important milestone, though much of the supporting clinical literature is published in Chinese-language databases (CNKI, Wanfang) and has not been rigorously replicated in large international RCTs. Independent corroboration through internationally registered, controlled trials is limited.

5.4 Antitumor Activity

Preclinical Evidence: Polysaccharides isolated from Tremella fuciformis have been demonstrated in laboratory settings to have anti-oxidative, anti-inflammatory, and anti-aging effects; additionally, TFPS has been used clinically as an antineoplastic agent as a safe and non-toxic natural active product. T. fuciformis has been demonstrated in laboratory studies to possess anticancer, anti-inflammation, anti-oxidative, and neuroprotective abilities. In melanoma cell models, increased lipid binding, upregulated lipid storage, and elevated triglyceride and lipid catabolism resulted in disruption of cell volume homeostasis and activated innate immune response, thus inhibiting melanoma development and progression, revealing a novel molecular mechanism involved in the antitumor effect of TFP via lipid metabolism.

Human/Clinical Evidence: Direct antitumor efficacy in human clinical trials is not established as of the available peer-reviewed literature. Clinical use of TFPS in oncology has been primarily as an adjuvant to manage chemotherapy-induced leukopenia and hepatotoxicity, rather than as a direct antitumor agent.

Evidence Strength: Preclinical only for direct antitumor effects. The adjuvant immunological use in cancer patients has regulatory recognition in China (see Section 5.3) but lacks robust independent international RCT data.

5.5 Skin Hydration and Dermatology

In Vitro / Mechanistic Evidence: Tremella fuciformis extract is considered a natural alternative to hyaluronic acid; it retains water deep in the skin cells and stimulates the skin to fight free radicals, which are responsible for the premature aging of the skin. A study by Chen and colleagues found the extract to be safe for ingestion and topical application; when used in skin care formulations, it has a similar or even better effect than hyaluronic acid on binding to water in the skin, influencing skin hydration by forming an occlusive layer on the skin surface.

In vitro studies with human skin cells, primarily dermal fibroblasts, and biochemical assays have identified various biological activities of polysaccharides extracted from Tremella fuciformis. In one in vitro multi-barrier model, quantification of intracellular hyaluronic acid confirmed that the hepatic eluate of fungal-derived HA led to a greater accumulation of HA within keratinocytes compared with both the control and sodium hyaluronate (about 45% vs. sodium hyaluronate, p < 0.05).

In one cosmetic formulation study, formulations containing Tremella fuciformis extract had the effect of reducing transepidermal water loss (TEWL) by 12.4%, compared to a formulation that did not contain this active ingredient.

Evidence Strength: The tremella-as-skin-supplement space has more marketing momentum than clinical evidence. No oral skin hydration RCT has been published — the beauty claims rest on in vitro fibroblast studies and mechanistic reviews, not human clinical trials. The cosmetic topical evidence is more robust for hydration effects than the evidence for oral supplementation producing dermatological outcomes.

5.6 Anti-inflammatory Effects

Preclinical Evidence: In a study comparing the therapeutic effects of topical or oral TFPS administration on atopic dermatitis in dinitrofluorobenzene (DNFB)-induced AD mice, both topical application and oral administration of TFPS led to improvement in transdermal water loss, epidermal thickening, and ear edema; the oral administration showed significantly better efficacy than topical application.

In a dextran sulfate sodium (DSS)-induced colitis mouse model, high-dose Tremella polysaccharides could prevent colon shortening, reduce myeloperoxidase and diamine oxidase activity, decrease D-lactate concentration, and alleviate colonic tissue damage; HTPs treatment stimulated Foxp3⁺ T cells and promoted the production of anti-inflammatory cytokines.

Evidence Strength: Preclinical only. Results from rodent models of colitis and atopic dermatitis are promising but have not been translated into published human RCTs for these indications.

5.7 Lipid Regulation (Hypolipidemic Effects)

Tremella fuciformis, being rich in adenosine, has been used for vascular thrombosis and in general for cardiovascular diseases, also for lipid-lowering, anticoagulant, and platelet anti-aggregating actions. Pharmacological activities reported include cytokine-stimulating, anti-tumor, anti-diabetic, anti-inflammatory, vascular-stimulating, cholesterol-lowering, antiallergic, and hepatoprotective effects. These effects have been described predominantly in animal and in vitro studies; human clinical evidence specifically for lipid lowering is limited.

Evidence Strength: Predominantly preclinical. Human evidence for standalone lipid-lowering effects is lacking as of the available peer-reviewed literature.

5.8 Antioxidant Activity

The ABTS⁺ radical scavenging activity of the chloroform subfraction of T. fuciformis methanol extract was 7.89 μmol trolox/mg extract, the highest among all subfractions; this subfraction also showed the highest DPPH radical scavenging activity and inhibitory activity of LDL oxidation. Researchers have reported that T. fuciformis polysaccharides possess antioxidant and anti-aging activities among other bioactivities.

Evidence Strength: Mechanistically well-characterized in in vitro and animal models. Antioxidant effects in humans as a standalone outcome have not been the primary endpoint of a registered RCT. These preclinical findings form the mechanistic basis for many of the other proposed health effects.

6. Body Systems and Health Areas of Association

• Immune system: Immunomodulatory and anti-radiation activities have been extensively characterized in preclinical studies and some clinical applications.
• Nervous system / brain: Preclinical data and one RCT support a potential role in neuroprotection and subjective cognitive impairment.
• Metabolic / endocrine system: One exploratory RCT in prediabetic individuals showed improvements in HbA1C and waist circumference.
• Integumentary system (skin): TFPS is studied as a natural alternative to hyaluronic acid for skin hydration and anti-aging topical formulations.
• Gastrointestinal system: Studies have identified protective effects of TFPs against DSS-induced colitis, including prevention of colon shortening and reduction of inflammatory markers.
• Hepatic system: TFPS is used as an adjuvant drug for treating chronic persistent hepatitis and chronic active hepatitis.
• Hematopoietic system: Enteric-coated TFPS capsules are approved in China specifically for chemotherapy- and radiotherapy-induced leukopenia.
• Respiratory system: Traditionally, Tremella has been used for soothing dry coughs and alleviating dryness-related respiratory conditions, though modern clinical evidence for respiratory indications is lacking.

7. Dosage Forms and Reported Dosages

The following dosages are those specifically reported in the cited scientific and traditional sources, and are not recommendations:

• Traditional oral preparation: Soaking approximately 3–4 grams for 1–2 hours, then cooking down to a paste in an earthenware pot.
• Dried fruiting body / mycelium (modern guideline): Up to 3.6 g of dried cultured mycelium/fruiting body per day is cited; for a decoction, 3 g of dried material in one cup of boiling water, simmered 15–20 minutes, drunk hot three times a day.
• Fresh or dried infusion (traditional pharmacopoeia reference): Tremella fuciformis can be eaten fresh or dried in infusions using 15 g twice daily (cited from Hobbs, 2000).
• Randomized controlled trial (cognitive impairment): 1,200 mg per day of TF administration was cited as a safe and easily accessible intervention for individuals with SCI in the published RCT.
• Randomized controlled trial (prediabetes): A once-daily beverage containing Tremella fuciformis was administered daily for 12 weeks to 56 participants in a double-blind RCT.
• Pharmaceutical (enteric-coated capsules, China): Tremella Polysaccharide Enteric-coated Capsules were approved by the Chinese SFDA in 2002 for treating leukopenia induced by chemotherapy and radiotherapy. Specific dosing schedules for this pharmaceutical form were not detailed in the available English-language peer-reviewed abstracts.

8. Safety Considerations and Interactions

The RCT authors noted that, to the best of their knowledge, there are no reports of major health risks associated with Tremella, and that 1,200 mg per day of TF administration was considered a safe and easily accessible intervention. In the same RCT, the overall frequency of adverse events did not differ statistically among the high-dose TF (40.4%), low-dose TF (35.1%), and placebo groups (41.4%).

In the prediabetes RCT, there were no adverse events reported in the Tremella fuciformis intervention group over 12 weeks.

Medicines derived from TFPs are primarily based on the natural active glycosyl component, offering broad applications, low toxicity, and minimal drug resistance. These characteristics are described as providing a significant advantage over synthetic medicines.

In summary, Tremella polysaccharides have been shown to possess various biological activities in experimental models; nonetheless, these effects are predominantly derived from in vitro experimental findings with some validated in animal models. Clinical trials remain limited. This means that the totality of evidence regarding long-term human safety is incomplete, particularly at supplemental doses higher than those tested in published trials.

Because in Traditional Chinese Medicine, co-administration of immunomodulatory agents and chemotherapy drugs is a recognized practice, and several immunoceuticals composed of polysaccharides are widely used; those immunomodulatory agents often act by inducing lymphocyte proliferation and cytokine production, and they have protective effects toward the hematopoietic function of bone marrow and immune organs — this immunostimulatory mechanism is relevant for individuals taking immunosuppressant drugs, where additive or antagonistic interactions are theoretically possible. No controlled human interaction data were identified in the available literature.

A practical safety consideration at the supply level is that Tremella products imported from large production areas have been noted to have issues with pesticide residues in some supply chains.

References

• Wu YJ, et al. Structure, bioactivities and applications of the polysaccharides from Tremella fuciformis mushroom: A review. Int J Biol Macromol. 2019;121:1005–1010. PubMed PMID: 30342120
• Yang H, et al. Tremella polysaccharide: The molecular mechanisms of its drug action. Prog Mol Biol Transl Sci. 2019. PubMed PMID: 31030755
• Bandara AR, et al. Morphological and Molecular Analysis Identifies the Associated Fungus of the Medicinal White Jelly Mushroom, Tremella fuciformis, as Annulohypoxylon stygium. PubMed PMID: 27481159
• Kim JH, et al. Antioxidant and anti-inflammatory activities of methanol extracts of Tremella fuciformis and its major phenolic acids. PubMed PMID: 24547933
• Han CK, et al. Comparison of Immunomodulatory and Anticancer Activities in Different Strains of Tremella fuciformis Berk. Am J Chin Med. 2015;43(8):1637–55. PubMed PMID: 26621447
• Recent advances in polysaccharides from Tremella fuciformis: isolation, structures, bioactivities and application. Frontiers in Nutrition. 2025. PMC12672291
• Tremella fuciformis Polysaccharides Inhibited Colonic Inflammation in Dextran Sulfate Sodium-Treated Mice via Foxp3+ T Cells, Gut Microbiota, and Bacterial Metabolites. PMC8049506
• Non-Animal Hyaluronic Acid from Tremella fuciformis: A New Source with a Structure and Chemical Profile Comparable to Hyaluronic Acid. Foods. 2025. PMC12027390
• Tremella fuciformis Polysaccharides Attenuate Oxidative Stress and Inflammation in Macrophages through miR-155. PMC5954968
• Tremella fuciformis polysaccharides alleviate induced atopic dermatitis in mice by regulating immune response and gut microbiota. Frontiers in Immunology. 2022. PMC9452665
• The Neuroprotective and Neurotrophic Effects of Tremella fuciformis in PC12h Cells. PMC3763079
• An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation. PMC9499394
• Tremella fuciformis beverage improves glycated hemoglobin A1c and waist circumference in overweight/obese prediabetic subjects: a randomized controlled trial. PMC10913275
• Ban S, et al. Efficacy and Safety of Tremella fuciformis in Individuals with Subjective Cognitive Impairment: A Randomized Controlled Trial. J Med Food. 2018;21(4):400–407.
• Effect of the Molecular Mass of Tremella Polysaccharides on Accelerated Recovery from Cyclophosphamide-Induced Leucopenia in Rats. PMC6268970
• Overcharged lipid metabolism in mechanisms of antitumor by Tremella fuciformis-derived polysaccharide. PMC9747192
• Optimization of the Composition of a Cosmetic Formulation Containing Tremella fuciformis Extract (Fungi). Cosmetics. 2023;10(3):82.
• Non-Animal Hyaluronic Acid from Tremella fuciformis: A New Source with a Structure and Chemical Profile Comparable to Hyaluronic Acid. Foods. 2025;14(8):1362.
• Jin Y, et al. Studies on the purification of polysaccharides separated from Tremella fuciformis and their neuroprotective effect. Mol Med Rep. 2016;13:3985–3992.
• Extraction, structure, biological activities of polysaccharides from Tremella fuciformis: A review. J Funct Foods. 2025.
• Structure, Function and Application of Tremella Fuciformis Polysaccharide: A Review. Journal of Food Science. 2025.
• Tremella fuciformis. Wikipedia (for taxonomic and morphological reference).
• Tremella fuciformis Berk. GBIF Backbone Taxonomy.
• NCBI Taxonomy Browser: Tremella fuciformis (Taxonomy ID: 64657).
• Absorption, Stability, and Bioactivity of Fungal-Derived Hyaluronic Acid from Tremella fuciformis in a Sequential In Vitro Multi-Barrier Model. PMC13074074
• Tremella (Tremella fuciformis): Benefits, Safety, Uses. Herbal Reality.